Wearable Auscultation Device Validation in Children

Sponsor
Strados Labs, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06112080
Collaborator
(none)
138
1
10.8
12.8

Study Details

Study Description

Brief Summary

This observational clinical study is an evaluation of a diagnostic tool through comparison. Similar to a validation study, the output of the RESP device will be compared to physician auscultation, surrogated by having an attending pulmonologist listen to blinded recordings.

Condition or Disease Intervention/Treatment Phase
  • Device: RESP™ Biosensor

Study Design

Study Type:
Observational
Anticipated Enrollment :
138 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Wearable Auscultation Device Validation in Children
Actual Study Start Date :
Aug 7, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Normal Breath Sound Cohort

32 patients ages 4-10, 16 patients ages 11-17) Admitted for a non-respiratory complaint Normal breath sounds on screening examination

Device: RESP™ Biosensor
The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
Other Names:
  • Remote Electronic Stethoscope Platform
  • Wheeze Cohort

    (106 patients ages 4-10, 53 patients ages 11-17) Admitted for pathologic process that may lead to wheezing (e.g., asthma) Presence of wheeze on screening examination

    Device: RESP™ Biosensor
    The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
    Other Names:
  • Remote Electronic Stethoscope Platform
  • Outcome Measures

    Primary Outcome Measures

    1. Compare the output of the RESP Biosensor System to breath sound interpretation of an attending physician via collected recordings from stethoscope and completion of a comparison questionnaire [12 months]

      PI will compare Strados RESP portal output with concurrent recordings collected via Littmann 300 Stethoscope. A questionnaire will be used to record and determine similarities and differences between RESP output and Littmann output, ultimately validating the intended use. Spectrographic data and audio recordings obtained via auscultation will be collected respectively by the RESP device and a separate recording stethoscope (Littman CORE Digital Stethoscope) simultaneously. Demographic and clinical data will be collected and stored in REDcap.

    Secondary Outcome Measures

    1. Tolerability and usability assessed utilizing The System Usibility Scale to evaluate attitudes towards the use and tolerance of the device by patients and caregivers [12 months]

      Assess the tolerability and usability of the Strados device by patients and caregivers utilizing the System Usability Scale will be used to evaluate subjects and caregivers attitudes towards the use and tolerance of the device. The System Usability Scale is a validated tool for evaluation of the usability and tolerability of a device or system by users. Then, subjects and caregivers will engage in a recorded interview using talk-aloud feedback. Recorded data will be transcribed and evaluated through quality analysis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    4 Years to 17 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Any child aged 4-17 years of age

    • Admitted to Lurie Children's Hospital or the Emergency Department at Lurie

    • Normal breath sounds cohort: (16 patients ages 4-10, 16 patients ages 11-17)

    • Admitted for a non-respiratory complaint

    • Normal breath sounds on screening examination

    • Wheeze cohort: (53 patients ages 4-10, 53 patients ages 11-17)

    • Admitted for pathologic process that may lead to wheezing (e.g., asthma)

    • Presence of wheeze on screening examination

    Exclusion Criteria:
    • Children less than age 4, adults (age 18 and above)

    • Patients in the ambulatory setting

    • Unable to provide consent

    • Intubated patients

    • Unstable disease posing a threat to life

    • Adhesive allergy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Lurie Children's Hospital of Chicago Chicago Illinois United States 60611

    Sponsors and Collaborators

    • Strados Labs, Inc.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Strados Labs, Inc.
    ClinicalTrials.gov Identifier:
    NCT06112080
    Other Study ID Numbers:
    • SL-LC01
    First Posted:
    Nov 1, 2023
    Last Update Posted:
    Nov 3, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 3, 2023